DUBLIN--(BUSINESS WIRE)--The "Global Organs-on-chips Market (2020-2025) by Type, Application, End-user Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
The Global Organs-on-chips Market is estimated to be USD 23.86 Mn in 2020 and is expected to reach USD 98.9 Mn by 2025, growing at a CAGR of 32.9%.
Market Dynamics
The growth of this market is mainly driven by the growing focus on developing alternatives for animal testing models, significant increase in research funding and venture capital investments for the development of organs-on-chips, technological advancements and new products launches, growing number of partnerships and collaborations between pharmaceutical companies and organs-on-chips manufacturers, and growing need for early detection of drug toxicity to minimize financial losses due to late stage drug failure.
Recent Developments
- CN Bio and Imperial College London collaborated to harness CN Bio's liver-on-chip technology to advance the understanding of the underlying mechanisms of alcoholic hepatitis and uncover novel targets for drug discovery and development.
- InSphero AG and ETH Bio Engineering Laboratory announced the license agreement for InSphero's Akura Flow organ-on-a-chip platform.
- Researchers at the US Army Combat Capabilities Development Command (CCDC) and Chemical Biological Center (CBC) used Emulat's lung on chip technology for research on COVID-19.
- Javelin Biotech and Pfizer entered a three-year development of a platform to evaluate absorption, distribution, metabolism, and excretion (ADME) properties of small molecules on an organ-on-a-chip platform. The platform will help inform human pharmacokinetic (PK) predictions, which are often crucial measurements evaluating new drug candidates in preclinical research. This further increased the growth in the market studied.
Company Profiles
Some of the companies covered in this report are 4DCell, Ascendance Biotechnology, Inc., AxoSim Technologies LLC, BeonChip, BiomimX SRL, Cherry Biotech, CN Bio Innovations, CN Biosystems, Elveflow, Emulate, Inc., HemoShear, TissUse GmbH, uFluidix Inc., etc.
Competitive Quadrant
The report includes a Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.
Why buy this report?
- The report offers a comprehensive evaluation of the Global Organs-on-chips Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
- The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
- The report includes in-depth market analysis using Porter's 5 force model and the Ansoff Matrix. The impact of Covid-19 on the market is also featured in the report.
- The report also contains the competitive analysis using the Competitive Quadrant, the analyst's proprietary competitive positioning tool.
Key Topics Covered:
1 Report Description
2 Research Methodology
3 Executive Summary
4 Market Overview
4.1 Introduction
4.2 Market Dynamics
4.2.1 Drivers
4.2.1.1 Growing Focus on Developing Alternatives for Animal Testing Models
4.2.1.2 Significant Increase in Research Funding and Venture Capital Investments for the Development of Organs-on-Chips
4.2.1.3 Technological Advancements and New Products Launches
4.2.1.4 Growing Number of Partnerships and Collaborations between Pharmaceutical Companies and Organs-on-Chips Manufacturers
4.2.1.5 Growing Need for Early Detection of Drug Toxicity to Minimize Financial Losses Due to Late Stage Drug Failure
4.2.1.6 Growing Initiatives to Increase Awareness about Organs-on-Chips Technologies
4.2.2 Restraints
4.2.2.1 Issues Related to the Incorporation of Organs-on-Chips Technologies Into Existing Workflows
4.2.3 Opportunities
4.2.3.1 Increasing Focus on Drug Discovery Activities
4.2.3.2 Application of Organs-on-Chips in Oncology Research
4.2.3.3 Development of Multiple-Organs-on-A-Chip Models
4.2.4 Challenges
4.2.4.1 Complexity of Organs-on-Chips Models
4.2.4.2 Dearth of Skilled Professionals
4.3 Trends
5 Market Analysis
5.1 Porter's Five Forces Analysis
5.2 Impact of COVID-19
5.3 Ansoff Matrix Analysis
6 Global Organs-on-chips Market, By Type
6.1 Introduction
6.2 Liver
6.3 Heart
6.4 Lung
6.5 Other Organ Types
7 Global Organs-on-chips Market, By Application
7.1 Introduction
7.2 Drug Discovery
7.3 Toxicology Research
7.4 Other Applications
8 Global Organs-on-chips Market, By End User
8.1 Introduction
8.2 Pharmaceutical and Biotechnology Companies
8.3 Academic and Research Institutes
8.4 Other End Users
9 Global Organs-on-chips Market, By Geography
10 Competitive Landscape
10.1 Competitive Quadrant
10.2 Market Share Analysis
10.3 Competitive Scenario
10.3.1 Mergers & Acquisitions
10.3.2 Agreement, Collaborations, & Partnerships
10.3.3 New Product Launches & Enhancements
10.3.4 Investments & Funding
11 Company Profiles
11.1 4DCell
11.2 Ascendance Biotechnology, Inc.
11.3 AxoSim Technologies LLC
11.4 BeonChip
11.5 BiomimX SRL
11.6 Cherry Biotech
11.7 CN Bio Innovations
11.8 CN Biosystems
11.9 Elveflow
11.10 Emulate, Inc.
11.11 HemoShear
11.12 Hurel Corporation
11.13 InSphero AG,
11.14 Kirkstall
11.15 Mesobiotech
11.16 Micronit
11.17 Mimetas B.V.
11.18 Nortis Inc.
11.19 Organovo Holdings, Inc.
11.20 SynVivo
11.21 Tara Biosystems Inc.
11.22 TissUse GmbH
11.23 uFluidix Inc.
For more information about this report visit https://www.researchandmarkets.com/r/4wi572
